Prospective Double-blind Placebo-controlled Study of the Effect of Xolair (Omalizumab) in Chronic Urticaria Patients

NCT01803763 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

COMPLETED

Status

30

Enrollment

OTHER

Sponsor class

Conditions

Chronic Urticaria
Chronic Idiopathic Urticaria
Chronic Spontaneous Urticaria

Interventions

DRUG: Omalizumab (Xolair)
DRUG: Placebo

Sponsor

Insel Gruppe AG, University Hospital Bern

Collaborators

[object Object]
[object Object]
[object Object]